Avid Bioservices Inc (CDMO)

[cheynew]

I also found it in this International New York Times reference:
http://topics.nytimes.com/top/news/business/companies/peregrine-pharmaceuticals-inc/index.html




LAST CHANGE VOLUME
AT CLOSE 10/30/2015 $1.12 +0.01 +0.90% 490.7K
AFTER HOURS 11/01/2015 $1.21 +0.09 +8.04%
Peregrine Pharmaceuticals Inc.
PPHM: Nasdaq; Healthcare/Biotechnology
PRIMARY EXCHANGE: NASDAQ
News about Peregrine Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.
COMPANY INFORMATION
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Company's therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.
Peregrine Pharmaceuticals Inc.
14282 Franklin Ave TUSTIN CA 92780
Phone: [phone]
Fax: [phone]

Web site
ARTICLES ABOUT PEREGRINE PHARMACEUTICALS INC.

NEWEST FIRST | OLDEST FIRST
PAGE:
? PREV1NEXT ?
SEARCH 1 ARTICLES:
SEARCH

GO
F.D.A. EXPEDITES REVIEW FOR PEREGRINE CANCER DRUG
Peregrine Pharmaceuticals Inc. said yesterday that the Food and Drug Administration had granted the company's experimental brain cancer drug an expedited review process if it was submitted for approval. F.D.A. reviews of experimental drugs typically...
October 11, 2001, Thursday
Advertising

Copyright © 2008. Quotes and other information supplied by independent providers identified on the vendor disclosures page.
PRICE CHART
1 day | 5 day | 3 month | 1 year | 5 year

Data delayed at least 15 minutes
View historical chart »
STOCK SNAPSHOT
Friday's open $1.12
Friday's close $1.12
52-week range

52-week high $1.66
52-week low $0.91
Market capitalization 226.4M
Avg. volume (10-day) 883.3K
Shares outstanding 202.1M
PPHM does not pay dividends
KEY FUNDAMENTALS
P/E ratio n.a.
Earnings per share –$0.29
Revenue $31.0M
Profit margin –164.59%
Return on equity –91.30%
Fundamentals are for the trailing